Skip to main content
Clinical Trials/NCT00163189
NCT00163189
Completed
Phase 3

Evolution Of Growth Rate In Children With Growth Retardation Related To Long-term Corticotherapy And Treated By Genotonorm

Pfizer19 sites in 1 country98 target enrollmentJanuary 2005

Overview

Phase
Phase 3
Intervention
Somatropin
Conditions
Growth Hormone Deficiency
Sponsor
Pfizer
Enrollment
98
Locations
19
Primary Endpoint
Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH treatment in such children

Registry
clinicaltrials.gov
Start Date
January 2005
End Date
December 2014
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Pfizer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Glucocorticosteroid treatment for 12 months at least
  • Bone age \< 15 years for a boy and \< 13 years for a girl
  • Child measured height \< - 2 SD, Child currently treated by GH

Exclusion Criteria

  • Known diabetes (type 1 or type 2)
  • A previous history of intolerance or hypersensitivity to the study drug or to drugs with similar chemical structures

Arms & Interventions

Somatropin

Intervention: Somatropin

Outcomes

Primary Outcomes

Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population

Time Frame: Baseline, Month 36

Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

Change From Baseline in Height Standard Deviation Score (SD) for Chronological Age (CA) at Month 36: Per Protocol (PP) Population

Time Frame: Baseline, Month 36

Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

Secondary Outcomes

  • Mean Height(Baseline, Month 12, 24, 36, 48, 60)
  • Mean Height Standard Deviation Score (SDS) for Bone Age (BA)(Baseline, Month 12, 24, 36, 48, 60)
  • Annual Growth Rate (AGR)(Baseline, Month 12, 24, 36, 48, 60)
  • Growth Rate (GR) Standard Deviation Score (SDS) for Bone Age (BA)(Month 12, 24, 36, 48, 60)
  • Body Mass Index (BMI)(Baseline, Month 12, 24, 36, 48, 60)
  • Growth Rate (GR) Standard Deviation Score (SDS) for Chronological Age (CA)(Baseline, Month 12, 24, 36, 48, 60)
  • Change From Baseline in Height at Month 12, 24, 36, 48 and 60(Baseline, Month 12, 24, 36, 48, 60)
  • Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, 24, 48 and 60(Baseline, Month 12, 24, 48, 60)
  • Change From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, 24, 36, 48 and 60(Baseline, Month 12, 24, 36, 48, 60)
  • Change From Baseline in Bone Age (BA) at Month 12, 24, 36, 48 and 60(Baseline, Month 12, 24, 36, 48, 60)
  • Ratio of Bone Age (BA) to Chronological Age (CA)(Baseline, Month 12, 24, 36, 48, 60)

Study Sites (19)

Loading locations...

Similar Trials